Cancer Immunology and Oncolytic Virology: Technologies and Global Markets

Published - May 2017| Analyst - Ufuk Ezer| Code - PHM129B
Cancer Immunology and Oncolytic Virology: Technologies and Global Markets
Single User License: $2750 Member Price: FREE

Report Highlights

The global cancer immunotherapy market should reach $96.5 billion by 2021 from $73.0 billion in 2016 at a compound annual growth rate (CAGR) of 5.7%, from 2016 to 2021.

Report Includes

  • An overview of the global markets for cancer immunotherapies and oncolytic virology.
  • Analyses of global market trends, with data from 2015, 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • Analyses of factors influencing market demand, such as clinical guidelines, demographic changes, and market saturation.
  • Information covering the latest trends, market structure, market size, key drug segments, and trends in technology.
  • Coverage of colony stimulating factors (CSFs), interferon alfa and gamma products, interleukin products and therapeutic monoclonal antibodies, including antibody conjugates, cancer vaccines, and other cancer treatment immunology products.
  • Technological discussions, including the current state, newly issued patents, and pending applications.
  • Profiles of leading companies in the industry.

Report Scope

The scope of this report covers current cancer immunotherapy markets for most common cancers. The market segments included in this report are therapeutic monoclonal antibodies (with special focus on checkpoint inhibitors), synthetic interleukins, interferons, and colony-stimulating factors; small kinase inhibitors of cancer-related targets; protective and therapeutic cancer vaccines; and adoptive cell therapies. This report also covers treatments that are in development for late-stage and early-stage oncolytic viruses. Detailed epidemiological information, discussion of incidence and mortality trends, overview of regulatory landscapes, and analysis of market shares for leading products and companies are also included in this report.

Analyst Credentials

Ufuk Ezer. Ezer holds a bachelor's degree in bioengineering and a master's degree in biotechnology, bioprocessing and business management. He possesses extensive pharmaceutical research and development experience and has participated in projects for various international institutions and organizations. Ezer has been granted scholarships and awards during his post-study works in countries such as Japan and Panama based on the high quality of his work and excellence in the fields of research.

Select reports include:

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Mar-2014| Analyst - Valerie Kellogg| Code - PHM129A

Report Highlights

The global cancer immunotherapies market reached $30.8 billion in 2012. This market is expected to grow to nearly $34.3 billion in 2013 and $67.9 billion in 2018 with a compound annual growth rate (CAGR) of 14.7% over the five-year period, 2013 to 2018.

Report Includes

  • An overview of the global market for cancer immunotherapies
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of CAGRs through 2018.
  • Analyses of factors influencing market demand such as clinical guidelines, demographic changes, and market saturation
  • Technological discussion including the current state, newly issued patents, and pending applications
  • Profiles of leading companies in the industry.

CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report